ENTA - NASDAQ
Enanta Pharmaceuticals, Inc.
$11.90
-1.1%Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotEnanta Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Enanta Pharmaceuticals, Inc. Income Statement
ENTA • NASDAQ
| Enanta Pharmaceuticals, Inc. Income Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||
65.3M | 67.6M | 79.2M | 86.2M | 97.1M | 122.5M | 205.2M | 206.6M | 102.8M | 88.3M | 160.9M | 47.7M | 32.1M | 41.7M | 41.9M | 22.8M | |
GROSS PROFIT | ||||||||||||||||
(4.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
60.7M | 67.6M | 79.2M | 86.2M | 97.1M | 122.5M | 205.2M | 206.6M | 102.8M | 88.3M | 160.9M | 47.7M | 32.1M | 41.7M | 41.9M | 22.8M | |
OPERATING INCOME | ||||||||||||||||
(146.1M) | (189.3M) | (216.4M) | (210M) | (206.6M) | (164.1M) | (168.5M) | (118.3M) | (78.2M) | (57.4M) | (36.7M) | (28.8M) | (23M) | (20.4M) | (16.6M) | (15.8M) | |
(43.9M) | (57.9M) | (52.9M) | (45.5M) | (32.5M) | (27.4M) | (26.2M) | (23.4M) | (20.7M) | (17M) | (13.5M) | (10M) | (6.2M) | (5.3M) | (5M) | (6.1M) | |
(106.7M) | (131.5M) | (163.5M) | (164.5M) | (174.1M) | (136.8M) | (142.2M) | (94.9M) | (57.5M) | (40.5M) | (23.2M) | (18.7M) | (16.8M) | (15.1M) | (11.5M) | (9.7M) | |
-85.3M | -121.7M | -137.2M | -123.8M | -109.6M | -41.6M | 36.7M | 88.3M | 24.6M | 30.8M | 124.1M | 19M | 9M | 21.3M | 25.3M | 6.9M | |
PRE-TAX INCOME | ||||||||||||||||
(7.7M) | (10.9M) | (5.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (4.9M) | (40K) | (45K) | (8K) | (18K) | (31K) | (0.0) | (3.2M) | (0.0) | |
1.8M | 3.8M | 6.2M | 1.6M | 2M | 6.5M | 8.8M | 4.9M | 2.5M | 1.7M | 960K | 449K | 217K | 118K | -3.1M | 14K | |
-4.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (283K) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.8M | 3.9M | 6.2M | 1.7M | 2M | 6.6M | 8.8M | 4.8M | 2.3M | 1.7M | 1.3M | 283K | 598K | 110K | -2M | 805K | |
-83.5M | -117.8M | -131M | -122.2M | -107.6M | -35M | 45.6M | 93.1M | 26.9M | 32.6M | 125.5M | 19.3M | 9.6M | 21.4M | 23.3M | 7.7M | |
NET INCOME | ||||||||||||||||
-1.7M | -1.7M | (2.8M) | -433K | -28.6M | (1.1M) | -826K | (21.2M) | (9.2M) | (10.9M) | (46.5M) | -15.2M | (0.0) | (0.0) | (0.0) | -157K | |
-81.9M | -116M | -133.8M | -121.8M | -79M | -36.2M | 46.4M | 72M | 17.7M | 21.7M | 79M | 34.4M | 9.6M | 21.4M | 23.3M | 7.9M |
SEC Filings
ENTA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 11, 2026 | 2026 | |
S-3 S-3 N/A | February 11, 2026 | February 11, 2026 | ||
10-Q 10-Q 2025 Q4 Q4 | February 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 09, 2026 | February 09, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | March 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | November 19, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 |
Related Guides
Continue your ENTA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.